Anna Eramo

Anna Eramo, MD, Psychiatrist, has been the Chief Medical Officer since Sep 2020. Dr. Eramo joins LB from Lundbeck, where she led United States Clinical and Medical Affairs with primary responsibilities extending across Lundbeck’s entire United States neurology and psychiatric portfolio of products, including brexpriprazole, vortioxetine, and Abilify Maintena. Dr. Eramo holds both an academic degree in medicine and a specialty degree in psychiatry and psychotherapy from the University Medical School of Naples, Italy.